3 Stocks Pushing The Drugs Industry Higher

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 57 points (-0.4%) at 13,961 as of Wednesday, Feb. 13, 2013, 11:45 AM ET. The NYSE advances/declines ratio sits at 1,624 issues advancing vs. 1,238 declining with 155 unchanged.

The Drugs industry currently is unchanged today versus the S&P 500, which is unchanged. A company within the industry that increased today was Sanofi ( SNY), up 0.9%.

TheStreet Ratings group would like to highlight 3 stocks pushing the industry higher today:

3. Pharmacyclics Incorporated ( PCYC) is one of the companies pushing the Drugs industry higher today. As of noon trading, Pharmacyclics Incorporated is up $5.23 (7.4%) to $75.60 on heavy volume Thus far, 678,885 shares of Pharmacyclics Incorporated exchanged hands as compared to its average daily volume of 545,200 shares. The stock has ranged in price between $72.25-$75.95 after having opened the day at $74.86 as compared to the previous trading day's close of $70.37.

Pharmacyclics, Inc. operates as a clinical-stage biopharmaceutical company focusing on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. Pharmacyclics Incorporated has a market cap of $4.9 billion and is part of the health care sector. The company has a P/E ratio of 50.5, above the S&P 500 P/E ratio of 17.7. Shares are up 22.4% year to date as of the close of trading on Tuesday. Currently there are 5 analysts that rate Pharmacyclics Incorporated a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Pharmacyclics Incorporated as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Pharmacyclics Incorporated Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

If you liked this article you might like

Johnson & Johnson Looks for New Deal That's Just Right

The Nominees for Best Biopharma CEO of 2015 Are...

Jim Cramer's 'Mad Money' Recap: Here's How Oil, the Fed and China Pushed Markets Up

AXON, REGN, BURL, FIVE: Jim Cramer's Views

The 10 Biggest U.S. M&A Deals in 2015